Kornimate/medical-research-clean huggingface dataset:
feasibility study: educational genetic test video

Conditions: Prostate Cancer; Education

Summary: assess whether introducing an educational video regarding the benefits, risks, and limitations of genetic testing affects prostate cancer patients' decisional conflict regarding receiving germline genetic testing.


Eligibility criteria:
inclusion criteria: * prostate cancer patients who have been prescribed germline genetic testing by their provider * understand written and spoken english * have not received germline genetic testing for hereditary cancer risk in the past exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant individuals * prisoners

Keywords: genetic testing education
treatment of strongyloides infection

Conditions: Strongyloides Stercoralis Infection; Strongyloidiasis

Summary: the aim of this study is to evaluate the serologic response in patients with s. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.

patients will be randomly assigned to receive 2 single doses of ivermectin at 200 µg/kg 2 weeks apart versus ivermectin at 200 µg/kg for 2 consecutive days. patients will be randomized 50-50 to the study groups using the date of birth and a random number table. all patients will be interviewed to obtain the medical history during the initial evaluation. patients will be asked about demographic data on a questionnaire written in english and spanish. physical exams, baseline blood cell counts, serum chemistries, htlv-1(human t-cell lymphotrophic virus) serology, an ige (immunoglobulin e), a stool sample for o \&p, and a pregnancy test will be performed as routine care all patients currently receive in our clinic.procedures: strongyloides serology will be performed in the parasitology laboratory of jacobi hospital with an in-house elisa that uses a 31-kda(kilodalton) recombinant protein antigen (termed nie) derived from l3 stage of s. stercoralis and purified from e. coli bl21 containing pet30b plasmid. once the in-house serology is performed serum will be banked, so it can be available to run in paired with samples taken during follow up visits. blood samples will be also collected and sent to the laboratory of parasitic diseases (lpd) at the niaid- national institutes of health (nih) to perform other serological techniques including the luciferase immunoprecipitation systems assay (lips) based on nie and the recombinant antigen s. stercoralis immunoreactive antigen (ssir). in addition, stools will be collected from all patients and will be fixated in saf(sodium acetate, acetic acid and formalin), to check for strongyloides stercoralis larvae. if possible, fresh stool will be obtained to check for larvae using the baermann technique and an aliquot will be frozen and sent to the nih for dna extraction and pcr(polymerase chain reaction as).

Eligibility criteria:
inclusion criteria: * at least 18 years of age * positive for strongyloides serology infection (as determined by elisa) exclusion criteria: * severe intestinal strongyloides infection * disseminated strongyloidiasis infection * pregnant and breastfeeding women * htlv-1 co-infection * patients with indeterminate results on strongyloides serology * patients who are immunosuppressed * unable to read and understand consent form

Keywords: ivermectin s. stercoralis parasite helminth filariform larvae baermann technique
magnetic stimulation as a treatment for stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the goal of this clinical trial is to determine the efficacy of electromagnetic stimulation treatment of the pelvic floor muscles in adult females with stress urinary incontinence.

a double-blinded randomized controlled clinical trial with a treatment arm and a sham treatment arm will be conducted; followed by an open label trial at 3 months for any sham treatment arm participants who do not meet treatment success. the primary goal is to compare the subjective success rates for the resolution of stress urinary incontinence (sui) for the magnetic stimulation treatment at 3 months. secondary aims include an assessment of complications, resolution of sui symptoms, patient bother from ui, quality of life and patient satisfaction. the proposed sample size is 158 patients. at the 3-month post treatment evaluation, the treatment allocation will be unmasked. patients will be followed post treatment up to 2 years.

Eligibility criteria:
inclusion criteria: 1) non-pregnant adult female, not planning pregnancy during the duration of the study 2) stress urinary incontinence (sui), as confirmed by history, focused evaluation for ≥3 months 3) objective proof of sui: observation of urine leakage by cough and valsalva (positive stress test) at a bladder volume of ≤ 300cc 4) bladder capacity ≥200cc 5) post void residual ≤100cc with stage i or lower pelvic organ prolapse 6) no concurrent or new planned treatment for sui during the treatment period and the 3 months following it 7) no known body metal from umbilicus to knees 8) willing and able to comply with the protocol. exclusion criteria: 1) patient is pregnant, lactating, or plans to become pregnant during the study; or patient is \<12 months post partum 2) patient has other predominant type of ui (e.g. urgency ui, overflow ui, fistula) 3) current chemo/radiotherapy; history of pelvic radiation; or pelvic surgery \< 3 months 4) systemic diseases known to affect bladder function (e.g. parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury) 5) current or history of urethral diverticulum, prior augmentation cystoplasty, implanted nerve stimulators for bladder symptoms 6) current evaluation or treatment for chronic pelvic pain 7) participation in another treatment intervention that might interfere with the results of this trial 8) patient has a medical condition or disorder that may cause non-compliance with the protocol (e.g. unable to perform self-evaluations and/or accurately report medical history, and/or data). 9) patient has ambulatory 24-hour pad test, where the increased pad weight is \< 3 grams. 10) patient is non-ambulatory (ambulatory with assistive devices allowed) or unable to sit in a chair independently 12) known body metal located from umbilicus to knees, or cardiac pacemaker 13) previous magnetic stimulation therapy

Keywords: electromagnetic stimulation therapy
exploration of the relationship between inflammation and integrity of the blood-brain barrier in suicidal behaviour

Conditions: Depression

Summary: recent studies have revealed an association between history of suicide attempt and inflammatory markers in both the cerebrospinal fluid and the plasma. post mortem studies have shown an increase in microglial activation in the brain tissue of suicide victims. however the relationship between peripheral and central inflammation in suicide is probably mediated by complex biological processes that are yet elucidated. an increase of blood s100b levels (biomarker of neurovascular damage; pmid 14530574) has been reported in adolescents with suicidal ideation vs. controls and independently of psychiatric disorder. the investigators hypothesize that peripheral inflammation may alter bbb which normally acts as a filter to ensure proper neuronal functioning in suicidal vs. non suicidal patients.

105 participants will be recruited : * 35 depressed patients having attempted suicide (maximum 3 attempts in life) * 35 depressed patients without history of suicide attempt (affective controls) * 35 healhy controls with no lifetime psychiatric history. only one visit is planned. a clinical assessment (2 hours) will be performed to characterise pschopathology and suicidal characteristics. blood and salivary samples will be obtained in order to measure inflammatory markers.

Eligibility criteria:
inclusion criteria: * 18-55 years old * able to understand nature, aims, and methodology of the study depending on the population : * current depressive episode (according to dsm-5 criteria) with a recent suicide attempt (within the 8 days before inclusion) and no more than 3 attempts in life * current depressive episode (according to dsm-5 criteria) without suicide attempt * no psychiatric history (according to dsm-5 criteria) exclusion criteria: * inflammatory diseases or intercurrent infections, or chronic diseases such as hepatitis c or b, hiv, alzheimer's, cancer or autoimmune disease * current antibiotic or anti-inflammatory treatments * refusal to participate * lifetime schizoaffective disorder or schizophrenia * on protective measures (guardianship or trusteeship) * deprived of liberty subject (administrative decision) * in exclusion period for another protocol * not affiliated to a social security agency * unable to understand and/or answer a questionnaire * pregnant or lactating women

Keywords: psychiatry blood brain barrie suicide attempt inflammation
yoga-mindfulness for pain management in inflammatory arthritis

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Pain

Summary: this study evaluates the potential effects on pain, pain-related symptoms and quality of life of a yoga-mindfulness program, compared to patient education and physiotherapy, for patients with inflammatory arthritis and persistent pain problems.

earlier studies has indicated that body-mind therapies such as yoga and tai chi might be beneficial in the management of chronic pain syndromes. chronic pain affects a large number of patients with inflammatory arthritis. effective treatments are lacking for this patient group, so new treatment strategies are warranted. the study is designed as randomized controlled trial where participants are allocated on a 1:1 ratio to either a 15 week intervention program of yoga-mindfulness or 15 weeks of patient education and mild physiotherapy. study outcomes include pain levels and other pain-related features such as fatigue, sleep problems, mood disturbances and functional disability as well as measurements of health-related quality of life.

Eligibility criteria:
inclusion criteria: * subject is 18 years of age or older * subject has a diagnosis of either rheumatoid arthritis or psoriatic arthritis * subject has a total score on siqr above 33 * subject has not changed anti-rheumatic or analgetic treatment strategies during the three months preceding study inclusion (dose changes of ongoing treatments are accepted) exclusion criteria: * subject has another medical condition that might prevent the subjects full participation in the interventions * subject has more than four swollen joints * subject has a c-reactive protein more than 20 mg/l * subject is currently practicing yoga or has practiced yoga regularly during the last six months prior to study inclusion * subject does not speak swedish * subject is unwilling to comply with the study protocol * subject is considered, by the investigator, to be an unsuitable candidate for the study
indicators of anastomotic leak after colorectal surgery

Conditions: Colorectal Cancer

Summary: we reviewed the patient underwent colorectal surgery with anastomosis and identified patients with anastomotic leak. then we started to figure out what blood investigation could be related to anastomotic leak.


Eligibility criteria:
inclusion criteria: * patient underwent colorectal surgery with anastomosis exclusion criteria: * patient has no colon or rectum as part of anastomosis * patient with more than one procedure within 6 month
ultrasound high bmi study

Conditions: Obesity Complicating Childbirth

Summary: this is a prospective experimental pilot study of full-term non-emergent obese parturients whose labor is being managed with epidural anesthesia to determine if neuraxial block placement with pre-procedure handheld ultrasound affects time to placement or number of needle passes. approximately 25 patients, presenting for delivery at the university of kentucky healthcare obstetrics department, will be randomized to either the ultrasound or palpation group, between study approval and 31 july 2022.

placement of neuraxial blocks is commonly achieved by palpating surface landmarks. this somewhat "blind" technique to identify the spinal space becomes more difficult and less reliable in obese patients. ultrasound devices have become common and successful with blocks and venous access, both involving mostly soft tissues. application of conventional ultrasound for neuraxial blocks has been limited by its bulkiness, limited imaging for bony structures and a long learning curve. a newly developed pocket-size ultrasound addresses these limitations by providing real-time pattern recognition for spinal bony structures and 3d overlay for recognition of midline spinous process and intervertebral space using an automated artificial intelligent algorithm. the hypothesis is that ultrasound guidance will reduce time to epidural placement and reduce number of passes in obese patients.

Eligibility criteria:
inclusion criteria: * subject requesting and consenting for a labor epidural, aged 18-50 and bmi between 35-59.9 at admission for labor. * subject with american society of anesthesiologists score equal to or less than iii. * subject with singleton gestation equal to or greater than 37 weeks. * subjects with planned labor epidural in sitting position. exclusion criteria: * patients with urgent or emergent diagnoses involving the health of the patient or child, such as abnormal fetal heart tracing. * patients with major back abnormalities (back surgery, significant scoliosis). * patients with contra-indication to neuraxial block (bleeding risk, local anesthetic allergy). * patients having cesarean section or combined spinal epidural. * patients whose epidurals are performed by residents in first month of obstetric rotation and/or having performed fewer than 20 labor epidurals in total. * patient needing a translator for procedure. * patients who are prisoners.

Keywords: high bmi, pregnancy, ultrasound
comparison of three batches of the japanese encephalitis vaccine ic51

Conditions: Japanese Encephalitis

Summary: the objective is to demonstrate equivalence of three ic51 batches in terms of geometric mean titers for anti-jev neutralizing antibody.

this is a randomized, controlled, multi-center, double blind phase 3 study. the study population consists of male and female healthy subjects, aged at least 18 years. 624 subjects will be enrolled at approximately 6 sites in study centers in austria and germany.

Eligibility criteria:
main inclusion criteria: * male and female subjects aged at least 18 years with written informed consent and either no childbearing potential or negative pregnancy test main exclusion criteria: * history of immunodeficiency or immunosuppressive therapy, known hiv, drug addiction including alcohol dependence
analgesic efficacy of genicular nerve block versus (ipack block ) in patients undergoing (acl) repair

Conditions: Post Operative Pain

Summary: one of the most common injuries to the knee is an anterior cruciate ligament (acl) sprain or tear due to trauma acl damage is crippling and often requires repair with an arthroscopic method, which is an outpatient surgery. nevertheless, patients experience severe postoperative pain on the first day after the acl reconstruction.efficient postsurgery pain management is an important part of patient recovery that is also crucial for their satisfaction.

the optimum role of peripheral nerve blocks in acl reconstruction continue to be debated as a component of multi-modal analgesia . as such ,an ideal block for aclr would target sensation but not motor function,have minimal complication risk,and be easily reproducible the genicular nerves include branches from the femoral, common peroneal, saphenous, tibial, and obturator nerves which innervate the knee capsule . the superolateral, superomedial, and inferomedial on the other hand, the interspace between the popliteal artery and capsule of the knee (ipack) block provides analgesia on the posterior knee joint, and the application of a genicular or ipack block has been be associated with promising outcomes following the aclr surgery

Eligibility criteria:
inclusion criteria: - patient age from 18 to 45 years old patient status asa i - ii patient body mass index (bmi) \<40 kg/m2 exclusion criteria: * -patients were excluded if they refused consent. * patients who are not cooperative. * bmi \>40 kg/m2. * allergy to local anesthetics. * patients with anticoagulation or bleeding problems. * previous nerve dysfunction. * physical status asa class iv.
clinical trial to compare the safety and efficacy of botulax® versus botox® in patients with cervical dystonia

Conditions: Cervical Dystonia

Summary: to determine the efficacy and safety of botulax® in treatment of cervical dystonia


Eligibility criteria:
inclusion criteria: 1. male or female of aged over 19 years 2. subjects diagnosed with primary cervical dystonia exclusion criteria: 1. subjects who have administered botulinum toxin within 16 weeks at the time of baseline 2. pregnant or nursing 3. females or males who do not agree on proper contraceptive measure
effects of hyperosmolar dextrose in rotator cuff disorder with bursitis

Conditions: Subacromial Bursitis

Summary: the main purpose of this study is to compare treatment efficacy of different concentration dextrose injection in chronic subacromial bursitis .

rotator cuff disorder with bursitis is one of the most frequent pathologies of the shoulder, which may cause serious restriction of daily activities and reduce quality of life. there are many ways in treating rotator cuff disorder with bursitis, including medication, physical therapy, kinesiological taping, acupuncture and local injection. protholotherapy, which inject hyperosmolar dextrose to soft tissue, is a novel management in musculoskeletal disorders. however, only few trials exist in studying hyperosmolar dextrose injection for rotator cuff disorder with bursitis and most of them have small sample size and not randomized. the aim of this study was to figure out the effects of sonographically guided subacromial bursa injection with hyperosmolar dextrose in rotator cuff disorder with bursitis by a randomized controlled trial.

Eligibility criteria:
inclusion criteria: 1. 20-65 years-old 2. pain lasting \>3 months 3. painful arc between 40° to 120° in abduction 4. positive neer and hawkins-kennedy tests 5. positive empty can test 6. pain in daily living activities 7. bursa thickness more than 2mm in ultrasound 8. rotator cuff tendinopathy exclusion criteria: 1. history of significant shoulder trauma 2. history of surgery, fracture, or dislocation 3. adhesive capsulitis 4. full thickness rotator cuff tear 5. a long head of bicep tendon tear 6. contra-indications to local dextrose injection (known blood coagulation disorders, warfarin therapy, allergy to dextrose) 7. previous shoulder steroid injection in one month 8. had any rheumatologic, systemic, or neurologic disorders 9. patients taking regular systemic nsaids or steroids 10. pregnant or breastfeeding mothers 11. malignancy
recombinant human thrombopoietin (rhtpo) in management of chemotherapy-induced thrombocytopenia in acute myelocytic leukemia

Conditions: Antineoplastic Adverse Reaction; Thrombocytopenia; Acute Myelocytic Leukemia

Summary: chemotherapy-related myelosuppression usually occurs in aml patients, which induces severe thrombocytopenia and haemorrhage, a leading cause of death. this clinical trial aims at evaluating efficacy and safety of rhtpo in management of chemotherapy-induced thrombocytopenia in acute myelocytic leukemia.

the investigators are undertaking a parallel group, multicentre, randomized controlled trial of 80 adults with chemotherapy-induced thrombocytopenia from 8 medical centers in china. aml patients with plt count \<30×10\^9/l during the previous cycle of chemotherapy are randomized into two groups that one receives rhtpo at 1.0μg/kg·d subcutaneously for 7\~14 consecutive days and the other receives no rhtpo or other thrombopoietic factor. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: * aml patients with plt count \<30×10\^9/l during the previous cycle of chemotherapy to minimize the risk of clinically significant bleeding. exclusion criteria: * allergic history to biological agents; history of thrombotic or hemorrhagic diseases; m3 or m7 subtype; pregnancy; hypertension; cardiovascular disease; diabetes; liver and kidney function impairment;

Keywords: chemotherapy-induced thrombocytopenia recombinant human thrombopoietin acute myelocytic leukemia
long term observation of patient satisfaction post intracor treatment based on patient perception and diagnostic data

Conditions: Presbyopia

Summary: this study is a prospective, open, not randomized, unilateral multicenter eye study consisting of two study arms to observe the long term satisfaction of patients after an intracor treatment. the satisfaction is determined with the help of the patient perception and the subjective / objective diagnostic data. the hypothesis of the study is that patients after an intracor treatment are satisfied in the long term.

the study is divided into two study arms. the first study arm includes patients of the preceding study "intrastromal correction of ametropia by femtosecond laser (study iscaf), study arm 1, presbyopia sub-group: treatment pattern 5-rings" and the second study arm includes patients of the previous "intrastromal presbyopia correction by means of femtosecond laser (study # 0905)". the hypothesis of the study is that patients after a intracor treatment are satisfied in the long term. by detailed patient information and a clarification conversation it is guaranteed that every interested and agreeing patient fulfils the inclusion criteria of this study. the quantitative measuring values of the patient perception are assessed by a questionnaire. for measuring the subjective / objective diagnostic data only certificated diagnostic devices are used. no invasive intervention in the eye will be made to change the visual acuity. within the scope of the study between 98 and 135 patients should be examined. 49 to 63 patient are intended for the first study arm and 49 to 72 for the second study arm. the follow-up examinations are carried out at 12 months and/or 24 months as well as for 36 months after the intracor treatment. the study end points are determined for all follow-up examinations. the aim criteria should be reached for the final examination, which is after 36 months, at the latest.

Eligibility criteria:
inclusion criteria: * age: at least 18 years old * patients must have read, understood and signed the patient information * patients are willing and able to return for follow-up examinations * patient has been already enrolled in the previous study "intrastromal correction of ametropia by femtosecond laser (study iscaf), study arm 1, presbyopia sub-group: treatment pattern 5-rings" or "intrastromal presbyopia correction by means of femtosecond laser (study # 0905)" exclusion criteria: * continual wearing of contact lenses before the follow-up examination . patients must refrain from wearing contact lenses for at least 14 days prior to these dates * patients who are pregnant or are lactating * patients who are participating in another ophthalmological clinical study except "intrastromal presbyopia correction by means of femtosecond laser (study # 0905)" * severe sick people who cannot give any information on their visual acuity

Keywords: presbyopia intracor patient satisfaction long term